Literature DB >> 16769961

Endothelial dysfunction in MELAS improved by l-arginine supplementation.

Y Koga1, Y Akita, N Junko, S Yatsuga, N Povalko, R Fukiyama, M Ishii, T Matsuishi.   

Abstract

The authors evaluated endothelial function in patients with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke) by flow-mediated vasodilation (FMD) and found a significant decrease vs controls. Two years of supplementation with oral l-arginine, a nitric oxide precursor, significantly improved endothelial function to control levels and was harmonized with the normalized plasma levels of l-arginine in patients. l-Arginine therapy improved endothelial dysfunction and showed promise in treating strokelike episodes in MELAS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769961     DOI: 10.1212/01.wnl.0000220197.36849.1e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

1.  Metabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS.

Authors:  Valerie Desquiret-Dumas; Naig Gueguen; Magalie Barth; Arnaud Chevrollier; Saege Hancock; Douglas C Wallace; Patrizia Amati-Bonneau; Daniel Henrion; Dominique Bonneau; Pascal Reynier; Vincent Procaccio
Journal:  Biochim Biophys Acta       Date:  2012-01-28

Review 2.  [Cerebral CT and MRI in mitchondrial disorders].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

3.  Effects of L-arginine on anatomical and electrophysiological deterioration of the eye in a rodent model of nonarteritic ischemic optic neuropathy.

Authors:  Hideki Chuman; Tomoyuki Maekubo; Takako Osako; Michitaka Ishiai; Naoko Kawano; Nobuhisa Nao-I
Journal:  Jpn J Ophthalmol       Date:  2013-05-29       Impact factor: 2.447

Review 4.  The neuro-ophthalmology of mitochondrial disease.

Authors:  J Alexander Fraser; Valérie Biousse; Nancy J Newman
Journal:  Surv Ophthalmol       Date:  2010-05-14       Impact factor: 6.048

5.  Arginine and citrulline for the treatment of MELAS syndrome.

Authors:  Ayman W El-Hattab; Mohammed Almannai; Fernando Scaglia
Journal:  J Inborn Errors Metab Screen       Date:  2017-03-24

6.  Stroke and Stroke-Like Symptoms in Patients with Mutations in the POLG1 Gene.

Authors:  Waleed Brinjikji; Jerry W Swanson; Carrie Zabel; Peter J Dyck; Jennifer A Tracy; Ralitza H Gavrilova
Journal:  JIMD Rep       Date:  2011-06-22

7.  8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease.

Authors:  Rebecca D Ganetzky; Marni J Falk
Journal:  Mol Genet Metab       Date:  2018-02-02       Impact factor: 4.797

Review 8.  Imaging of MELAS.

Authors:  Konark Malhotra; David S Liebeskind
Journal:  Curr Pain Headache Rep       Date:  2016-09

Review 9.  Mitochondrial biogenesis: regulation by endogenous gases during inflammation and organ stress.

Authors:  Hagir B Suliman; Claude A Piantadosi
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

10.  Retinal dystrophy associated with a single-base deletion mutation in mitochondrial DNA 3271 in patient with MELAS syndrome.

Authors:  Kenji Ozawa; Kiyofumi Mochizuki; Yusuke Manabe; Nobuaki Yoshikura; Takayoshi Shimohata; Ichizo Nishino; Yu-Ichi Goto
Journal:  Doc Ophthalmol       Date:  2019-01-30       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.